Report cover image

Plasma Fractionation Market Growth, Size, Trends Analysis - By Product, By Method, By Application, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published Jan 21, 2025
Length 246 Pages
SKU # SPER19635547

Description

Plasma Fractionation Market Introduction and Overview

According to SPER market research, ‘Plasma Fractionation Market Growth, Size, Trends Analysis – By Product, By Method, By Application, By End-User – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Plasma Fractionation Market is predicted to reach 82.93 billion by 2034 with a CAGR of 8.73%.

Plasma fractionation is a manufacturing technique that separates plasma proteins for use in various therapies. Human plasma fractionation provides the foundation for producing a number of life-saving protein medicines, including coagulation factors, albumin, immunoglobulins, protease inhibitors, and more. These plasma-derived pharmaceutical preparations are commonly used in clinical settings to replace intravenous protein therapy in the treatment of immunological, hemostatic, metabolic, and other life-threatening illnesses.

Restraints:The emergence of recombinant therapies as an alternative to plasma-derived medicines restrains market growth. The recombinant product performance of plasma-derived products is achieved by producing similar proteins in genetically modified cells. It is safer than plasma-derived products because it prevents the transfer of bloodborne diseases. The development of recombinant therapeutics as an alternative to plasma-derived medicines has slowed growth.

Scope of the Report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034

Segments covered

By Product, By Method, By Application, By End-User.
Regions covere
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Grifols S.A, CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Kedrion S.p.A, LFB S.A, Biotest AG, Sanquin, Bio Products Laboratory Ltd, Intas Pharmaceuticals Ltd.

Plasma Fractionation Market Segmentation:

By Product:Based on the Product, Global Plasma Fractionation Market is segmented as; Albumin, Immunoglobulins, Coagulation Factors, Protease inhibitors, Others.

By Method:Based on the Method, Global Plasma Fractionation Market is segmented as; Centrifugation, Depth Filtration, Chromatography, Others.

By Application:Based on the Application, Global Plasma Fractionation Market is segmented as; Neurology, Hematology, Oncology, Immunology, Pulmonology, Others.

By End User:Based on the End Use, Global Plasma Fractionation Market is segmented as; Hospitals & Clinics, Clinical Research, Others.

By Region:This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

246 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Plasma Fractionation Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Plasma Fractionation Market
7. Global Plasma Fractionation Market, By Product (USD Million) 2021-2034
7.1. Albumin
7.2. Immunoglobulins
7.2.1. Intravenous immunoglobulins
7.2.2. Subcutaneous immunoglobulins
7.2.3. Other immunoglobulins
7.3. Coagulation Factors
7.3.1. Factor VIII
7.3.2. Factor IX
7.3.3. VON WILLEBRAND factor
7.3.4. Prothrombin complex concentrates
7.3.5. Fibrinogen concentrates
7.3.6. Others
7.4. Protease inhibitors
7.5. Others
8. Global Plasma Fractionation Market, By Method (USD Million) 2021-2034
8.1. Centrifugation
8.2. Depth Filtration
8.3. Chromatography
8.4. Others
9. Global Plasma Fractionation Market, By Application (USD Million) 2021-2034
9.1. Neurology
9.2. Hematology
9.3. Oncology
9.4. Immunology
9.5. Pulmonology
9.6. Others
10. Global Plasma Fractionation Market, By End User (USD Million) 2021-2034
10.1. Hospitals & Clinics
10.2. Clinical Research
10.3. Others
11. Global Plasma Fractionation Market, (USD Million) 2021-2034
11.1. Global Plasma Fractionation Market Size and Market Share
12. Global Plasma Fractionation Market, By Region, (USD Million) 2021-2034
12.1. Asia-Pacific
12.1.1. Australia
12.1.2. China
12.1.3. India
12.1.4. Japan
12.1.5. South Korea
12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France
12.2.2. Germany
12.2.3. Italy
12.2.4. Spain
12.2.5. United Kingdom
12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia
12.3.2. United Arab Emirates
12.3.3. Qatar
12.3.4. South Africa
12.3.5. Egypt
12.3.6. Morocco
12.3.7. Nigeria
12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada
12.4.2. Mexico
12.4.3. United States
12.5. Latin America
12.5.1. Argentina
12.5.2. Brazil
12.5.3. Rest of Latin America
13. Company Profile
13.1. Grifols S.A
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. CSL Limited
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Takeda Pharmaceutical Company Limited
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Octapharma AG
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Kedrion S.p.A
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. LFB S.A
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Biotest AG
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Sanquin
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Bio Products Laboratory Ltd
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Intas Pharmaceuticals Ltd
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us